Study suggests that immunotherapy is more effective than chemotherapy at treating people with advanced lung cancer
Researchers in the USA have found that an immunotherapy drug is more effective at treating people with advanced lung cancer than standard chemotherapy drugs.
The study, published in The Lancet, involved more than 1,000 participants with a certain type of non-small cell lung cancer who had previously received treatment for their condition.
Participants were randomly selected to receive a course of the immunotherapy drug, pembrolizumab, or docetaxel, the standard chemotherapy drug.
The researchers found that the people who were treated with immunotherapy lived longer than those who were given chemotherapy, and that their tumours were more likely to shrink by a significant amount.
This finding could offer new hope for lung cancer treatment that avoids the toxicity associated with chemotherapy.
Pembrolizumab was licensed for use by the European Medicines Agency for the treatment of skin cancer in July. It is not currently licensed for the treatment of lung cancer.